Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21962329 | 0.74 | CCNB2 (0.35) | KDM4ELMNACYP2D6 | |
| SCHEMBL20698724 | 0.71 | MTNR1A (0.32) | LMNACYP2D6 | |
| SCHEMBL3912453 | 0.71 | P2RX7 (0.41) | P2RX7CYP2D6 | |
| SCHEMBL508531 | 0.69 | P2RX7 (0.43) | P2RX7LMNA | |
| SCHEMBL20468260 | 0.68 | P2RX7 (0.39) | P2RX7 | |
| SCHEMBL23319812 | 0.68 | CCNB2 (0.35) | KDM4ECYP2D6 | |
| SCHEMBL9608998 | 0.68 | KDM4E (0.35) | P2RX7KDM4ELMNA | |
| SCHEMBL6559444 | 0.67 | KDM4E (0.48) | P2RX7KDM4ELMNA | |
| SCHEMBL508945 | 0.67 | P2RX7 (0.31) | P2RX7KDM4ELMNA | |
| SCHEMBL20698993 | 0.66 | MTNR1A (0.36) | KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2528901-B9 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2017-01-25 | — | — | EP | disclosed |
| EP-2528901-B1 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2015-05-27 | — | — | EP | disclosed |
| US-8791272-B2 | Pyrazole compounds as CRTH2 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| EP-2528901-A1 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2012-12-05 | — | — | EP | disclosed |
| US-20120028938-A1 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
| WO-2011092140-A1 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028938-A1 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | HRH2, HRH1, HRH3 | P2RX7 40/4885KDM4E 4438/4885LMNA 3633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.